Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
8212-Preserved: CDR132L in Heart Failure With Preserved Ejection Fraction
NCT06979362Phase 2Recruiting
- Sponsor
- Novo Nordisk
- Start
- Jun 2025
- Primary completion
- Nov 2027
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 9
01
Overview
A Phase 2 trial of CDR132L in heart failure (HF), sponsored by Novo Nordisk. Started Jun 2025; status: recruiting.
02
Drugs
CDR132L
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06979362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06979362.